These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37482751)

  • 1. Implementing outcomes-based risk-sharing agreements: an integrative review of applications in blood cancer in the UK and beyond.
    Bayani DB; Wee HL
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(8):879-889. PubMed ID: 37482751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory, Policy, and Operational Considerations for Outcomes-Based Risk-Sharing Agreements in the U.S. Market: Opportunities for Reform.
    Goodman C; Villarivera C; Gregor K; van Bavel J
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1174-1181. PubMed ID: 31535596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value-based payment for high-cost treatments in Singapore: a qualitative study of stakeholders' perspectives.
    Bayani DB; Wee HL
    Int J Technol Assess Health Care; 2024 Apr; 40(1):e22. PubMed ID: 38629196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance-based risk-sharing agreements in renal care: current experience and future prospects.
    Drummond M; Federici C; Busink E; Apel C; Kendzia D; Brouwer W
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):197-209. PubMed ID: 33439090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stakeholder views of managed entry agreements: A literature review of national studies.
    Thanimalai S; Choon WY; Lee KK
    Health Policy Open; 2021 Dec; 2():100032. PubMed ID: 37383516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
    Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
    Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facilitators, barriers and considerations for the implementation of healthcare innovation: A qualitative rapid systematic review.
    Parmar J; Sacrey LA; Anderson S; Charles L; Dobbs B; McGhan G; Shapkin K; Tian P; Triscott J
    Health Soc Care Community; 2022 May; 30(3):856-868. PubMed ID: 34558143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
    Buyukkaramikli NC; Wigfield P; Hoang MT
    Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk sharing in managed entry agreements-A review of the Swedish experience.
    Andersson E; Svensson J; Persson U; Lindgren P
    Health Policy; 2020 Apr; 124(4):404-410. PubMed ID: 32093981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
    Towse A; Garrison LP
    Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment.
    Grimm SE; Strong M; Brennan A; Wailoo AJ
    Pharmacoeconomics; 2017 Dec; 35(12):1287-1296. PubMed ID: 28849538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature.
    Czoski-Murray C; Lloyd Jones M; McCabe C; Claxton K; Oluboyede Y; Roberts J; Nicholl JP; Rees A; Reilly CS; Young D; Fleming T
    Health Technol Assess; 2012 Dec; 16(50):i-xvi, 1-159. PubMed ID: 23302507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.
    Morel T; Arickx F; Befrits G; Siviero P; van der Meijden C; Xoxi E; Simoens S
    Orphanet J Rare Dis; 2013 Dec; 8():198. PubMed ID: 24365263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementing and using quality measures for children's health care: perspectives on the state of the practice.
    Shaller D
    Pediatrics; 2004 Jan; 113(1 Pt 2):217-27. PubMed ID: 14702504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.